Supplier
ST Elizabeth Medical Center, INC
ST Elizabeth Medical Center, INC was paid $188.25M by Medicaid between Jan 2018 and Dec 2024, across 628 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoST ELIZABETH MEDICAL CENTER, INC
EDGEWOOD, KY 41017
EDGEWOOD, KY 41017
33aNPI1467492421assigned 06/07/2006
33bProvider typePortable X-ray and/or Other Portable Diagnostic Imaging Supplier
28Total paid$188.25M
24GClaims4,271,419
24DCodes billed628
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Portable X-ray and/or Other Portable Diagnostic Imaging Supplier providers in Kentucky
Rank by total paid#1 of 5
Median peer was paid$73K
This provider vs. median2,574×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 583,342 | $23.08M | |
| 2019 | 567,418 | $23.11M | |
| 2020 | 564,111 | $24.00M | |
| 2021 | 638,658 | $26.55M | |
| 2022 | 648,719 | $27.43M | |
| 2023 | 701,594 | $34.01M | |
| 2024incomplete | 567,577 | $30.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 115,681 | 98,046 | $26.28M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 53,269 | 41,836 | $17.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 25,230 | 15,623 | $9.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 38,673 | 35,654 | $5.74M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 46,787 | 32,028 | $4.34M |
| G0378 | Hospital observation service, per hour | 2.2% | 20,058 | 8,343 | $4.18M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 70,350 | 55,062 | $4.16M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.2% | 574 | 389 | $4.09M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.2% | 49,231 | 37,224 | $4.06M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 44,765 | 41,601 | $3.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 14,655 | 13,404 | $3.13M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.5% | 11,620 | 5,810 | $2.85M |
616 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 23,294 | $2.33M |
| 93458 | 1.2% | 1,624 | $2.30M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 7,640 | $2.22M |
| 59025 | Fetal non-stress test | 1.1% | 17,315 | $2.14M |
| J3490 | Unclassified drugs | 1.1% | 145,777 | $2.05M |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 428,575 | $2.00M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 4,040 | $1.74M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 41,045 | $1.72M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 24,524 | $1.72M |
| 80053 | Comprehensive metabolic panel | <1% | 195,508 | $1.69M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,940 | $1.62M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 45,583 | $1.54M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 44,772 | $1.52M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 30,340 | $1.38M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,642 | $1.37M |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 88,558 | $1.36M |
| 81514 | <1% | 11,981 | $1.36M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 43,771 | $1.34M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 41,247 | $1.33M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 11,117 | $1.28M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 9,761 | $1.24M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 31,690 | $1.24M |
| 76818 | <1% | 12,566 | $1.19M | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,761 | $1.16M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 38,909 | $1.08M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,050 | $1.07M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 6,085 | $1.04M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 10,096 | $1.02M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 174,633 | $1.02M |
| 80061 | Lipid panel | <1% | 84,808 | $981K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,536 | $969K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,628 | $955K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 39,368 | $918K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,578 | $911K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13,219 | $898K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38,365 | $882K |
| 11043 | <1% | 2,294 | $878K | |
| 71045 | Radiologic examination, chest; single view | <1% | 20,247 | $865K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,717 | $826K |
| 64721 | <1% | 767 | $806K | |
| C1776 | Joint device (implantable) | <1% | 561 | $779K |
| 77386 | <1% | 2,064 | $775K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 7,151 | $681K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,672 | $681K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,155 | $674K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 4,265 | $670K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,137 | $591K |
| 76801 | <1% | 6,440 | $587K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,894 | $567K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,088 | $541K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 22,750 | $520K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 55,390 | $511K |
| 87902 | <1% | 2,177 | $500K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14,579 | $494K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,914 | $486K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 81,390 | $478K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,038 | $476K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,413 | $464K |
| 80074 | <1% | 9,687 | $462K | |
| 96367 | <1% | 8,823 | $456K | |
| 36591 | <1% | 8,520 | $450K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,973 | $450K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 63,623 | $447K |
| 96376 | <1% | 11,758 | $439K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,232 | $430K |
| 10060 | <1% | 2,676 | $427K | |
| 93017 | <1% | 3,060 | $425K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,935 | $421K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13,175 | $385K |
| 77066 | Tomosynthesis, mammo | <1% | 4,634 | $381K |
| 77336 | <1% | 5,173 | $374K | |
| 82607 | <1% | 22,834 | $369K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 12,125 | $366K |
| 95886 | <1% | 3,489 | $366K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 18,352 | $349K |
| 76642 | <1% | 5,287 | $331K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,640 | $330K |
| 85027 | <1% | 65,325 | $329K | |
| 72100 | <1% | 6,601 | $329K | |
| 47562 | <1% | 458 | $320K | |
| 84702 | <1% | 33,736 | $305K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,899 | $301K |
| 72141 | <1% | 1,805 | $298K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 21,641 | $297K |
| 95911 | <1% | 842 | $289K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 97 | $279K |
| 86900 | <1% | 15,681 | $275K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,002 | $274K |
| 77334 | <1% | 524 | $259K | |
| 96415 | <1% | 3,544 | $257K | |
| 12001 | <1% | 2,454 | $251K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,351 | $251K |
| 73630 | <1% | 7,137 | $247K | |
| 97162 | <1% | 4,380 | $245K | |
| 88342 | <1% | 3,147 | $241K | |
| 71250 | <1% | 3,469 | $237K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,773 | $235K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 6,171 | $235K |
| 87522 | Neg quan hep c or qual rna | <1% | 6,285 | $233K |
| 97161 | <1% | 6,497 | $224K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,806 | $223K |
| 94726 | <1% | 1,582 | $223K | |
| 88307 | <1% | 1,893 | $220K | |
| 87653 | <1% | 6,773 | $218K | |
| 73564 | <1% | 4,824 | $218K | |
| 84439 | <1% | 24,809 | $217K | |
| 27447 | <1% | 87 | $207K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 9,733 | $205K |
| 82746 | <1% | 14,315 | $205K | |
| 73130 | <1% | 5,606 | $202K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 355 | $200K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,643 | $199K |
| 86780 | <1% | 16,459 | $196K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,999 | $191K |
| 77412 | <1% | 1,134 | $191K | |
| 29125 | <1% | 2,130 | $191K | |
| 84484 | <1% | 29,961 | $191K | |
| 80076 | <1% | 25,344 | $191K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,018 | $185K |
| 87481 | <1% | 2,954 | $184K | |
| 70491 | <1% | 1,368 | $182K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,709 | $182K |
| 93971 | <1% | 2,369 | $178K | |
| 86003 | <1% | 1,669 | $175K | |
| 73610 | <1% | 5,408 | $173K | |
| 82962 | <1% | 27,035 | $170K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 31,162 | $169K |
| 93880 | <1% | 1,518 | $168K | |
| 93225 | <1% | 2,294 | $168K | |
| 71271 | <1% | 2,180 | $164K | |
| 87077 | <1% | 20,022 | $162K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,953 | $160K |
| 12011 | <1% | 1,533 | $160K | |
| 97010 | <1% | 22,472 | $157K | |
| 96417 | <1% | 2,383 | $156K | |
| 73030 | <1% | 4,503 | $151K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,682 | $151K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 45,111 | $147K |
| 93970 | <1% | 972 | $147K | |
| 84403 | <1% | 5,992 | $144K | |
| 77300 | <1% | 500 | $139K | |
| 76942 | <1% | 2,075 | $139K | |
| 86481 | <1% | 1,707 | $137K | |
| 70486 | <1% | 1,778 | $136K | |
| 82728 | <1% | 10,134 | $135K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,225 | $134K |
| 72050 | <1% | 2,304 | $133K | |
| 70496 | <1% | 1,268 | $132K | |
| 29881 | <1% | 112 | $129K | |
| 76770 | <1% | 1,875 | $127K | |
| 87186 | <1% | 16,533 | $125K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,261 | $125K |
| 74018 | <1% | 3,573 | $124K | |
| 83690 | <1% | 28,739 | $123K | |
| 83970 | <1% | 3,419 | $121K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,707 | $121K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 241 | $119K |
| 76536 | <1% | 1,418 | $114K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,226 | $114K |
| 77065 | Tomosynthesis, mammo | <1% | 2,107 | $114K |
| 73110 | <1% | 3,580 | $112K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,684 | $112K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 23,156 | $110K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 2,054 | $109K |
| 83880 | <1% | 5,020 | $107K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 534 | $107K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,139 | $106K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 162 | $105K |
| 73502 | <1% | 3,178 | $101K | |
| 82565 | <1% | 8,358 | $99K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 2,550 | $98K |
| 70498 | <1% | 1,295 | $97K | |
| 76820 | <1% | 2,148 | $96K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12,950 | $95K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,788 | $95K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 16,271 | $94K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 20,422 | $93K |
| 87510 | <1% | 4,333 | $92K | |
| 87480 | <1% | 4,488 | $92K | |
| 86850 | <1% | 13,796 | $92K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 151 | $92K |
| 87631 | <1% | 895 | $91K | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 3,733 | $90K |
| 87650 | <1% | 3,637 | $88K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 161 | $87K |
| 94010 | <1% | 1,116 | $86K | |
| 87660 | <1% | 4,007 | $85K | |
| 87070 | <1% | 11,049 | $85K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 4,929 | $84K |
| 84153 | <1% | 5,417 | $84K | |
| 93226 | <1% | 1,756 | $83K | |
| 83550 | <1% | 10,619 | $81K | |
| 64447 | <1% | 359 | $80K | |
| 86803 | <1% | 6,737 | $80K | |
| 86762 | <1% | 6,552 | $80K | |
| 87340 | <1% | 9,495 | $80K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,399 | $80K |
| 95811 | <1% | 127 | $78K | |
| 81001 | <1% | 35,902 | $76K | |
| 83540 | <1% | 12,749 | $75K | |
| 85610 | <1% | 20,248 | $74K | |
| 84481 | <1% | 4,809 | $73K | |
| 73221 | <1% | 445 | $72K | |
| 82570 | <1% | 13,702 | $70K | |
| 83735 | <1% | 13,480 | $70K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 686 | $70K |
| 86140 | <1% | 15,375 | $70K | |
| 87536 | <1% | 851 | $68K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,637 | $68K |
| 94729 | <1% | 1,343 | $68K | |
| 12002 | <1% | 752 | $67K | |
| 91200 | <1% | 703 | $67K | |
| 86706 | <1% | 6,117 | $67K | |
| 83001 | <1% | 3,537 | $66K | |
| 73562 | <1% | 1,411 | $66K | |
| 96411 | <1% | 941 | $65K | |
| 75574 | <1% | 480 | $65K | |
| 88341 | <1% | 686 | $64K | |
| 95910 | <1% | 352 | $64K | |
| 82533 | <1% | 4,029 | $64K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,736 | $63K |
| 73080 | <1% | 2,049 | $63K | |
| 88304 | <1% | 2,452 | $62K | |
| 73140 | <1% | 1,913 | $62K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,878 | $62K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,322 | $61K |
| 96416 | <1% | 239 | $60K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,101 | $60K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,280 | $58K |
| 29515 | <1% | 464 | $56K | |
| 84146 | <1% | 3,042 | $56K | |
| 58571 | <1% | 40 | $56K | |
| 87205 | <1% | 14,249 | $56K | |
| 96368 | <1% | 1,109 | $56K | |
| 87088 | <1% | 8,077 | $56K | |
| 83605 | <1% | 9,302 | $55K | |
| 82043 | <1% | 9,326 | $55K | |
| 94761 | <1% | 2,058 | $52K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 145 | $52K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,078 | $51K |
| 77080 | <1% | 928 | $51K | |
| J1815 | Injection, insulin, per 5 units | <1% | 8,348 | $51K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,025 | $50K |
| 82077 | <1% | 5,398 | $50K | |
| 83002 | <1% | 2,813 | $50K | |
| 82670 | <1% | 1,715 | $49K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,269 | $49K |
| 85379 | <1% | 8,021 | $49K | |
| 97016 | <1% | 5,089 | $49K | |
| 96523 | <1% | 1,420 | $48K | |
| 19083 | <1% | 48 | $48K | |
| 81025 | <1% | 5,760 | $48K | |
| 99219 | <1% | 955 | $48K | |
| 73590 | <1% | 1,524 | $48K | |
| 83516 | <1% | 3,515 | $47K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 133 | $46K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 213 | $46K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 776 | $46K |
| 86038 | <1% | 4,340 | $45K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 17,854 | $45K |
| 86235 | <1% | 1,343 | $44K | |
| 82024 | <1% | 1,068 | $43K | |
| 84703 | <1% | 8,542 | $42K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,298 | $42K |
| 97014 | <1% | 3,445 | $41K | |
| 90715 | <1% | 2,778 | $41K | |
| 81003 | <1% | 22,198 | $40K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 24,915 | $40K |
| 29848 | <1% | 40 | $40K | |
| 64415 | <1% | 662 | $39K | |
| 71101 | <1% | 774 | $39K | |
| 82784 | <1% | 3,195 | $38K | |
| 97165 | <1% | 644 | $37K | |
| 80069 | <1% | 3,984 | $37K | |
| 82803 | <1% | 2,696 | $37K | |
| 87046 | <1% | 1,501 | $35K | |
| 93798 | <1% | 550 | $35K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 407 | $35K |
| 87808 | <1% | 5,802 | $34K | |
| 84550 | <1% | 8,422 | $34K | |
| 85652 | <1% | 13,937 | $34K | |
| 86901 | <1% | 16,105 | $32K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 3,485 | $32K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,642 | $32K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 420 | $32K |
| 93923 | <1% | 368 | $31K | |
| 87529 | <1% | 939 | $31K | |
| 73090 | <1% | 1,074 | $31K | |
| 86480 | <1% | 538 | $31K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,046 | $30K |
| 73700 | <1% | 353 | $29K | |
| 82985 | <1% | 1,977 | $29K | |
| 76937 | <1% | 563 | $28K | |
| 59812 | <1% | 15 | $28K | |
| 82785 | <1% | 1,566 | $28K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,101 | $28K |
| 93325 | <1% | 389 | $28K | |
| 84402 | <1% | 1,197 | $28K | |
| 87430 | <1% | 5,337 | $27K | |
| 72070 | <1% | 433 | $27K | |
| 84145 | <1% | 1,886 | $27K | |
| 72072 | <1% | 818 | $27K | |
| 76870 | <1% | 492 | $26K | |
| 94060 | <1% | 144 | $26K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,480 | $26K |
| 97163 | <1% | 379 | $26K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,285 | $26K |
| 87040 | <1% | 4,317 | $24K | |
| 86200 | <1% | 1,951 | $24K | |
| 85730 | <1% | 5,768 | $24K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,848 | $23K |
| 97113 | <1% | 426 | $23K | |
| 86376 | <1% | 1,802 | $23K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,264 | $22K |
| 82550 | <1% | 3,977 | $22K | |
| 82248 | <1% | 4,960 | $22K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 334 | $22K |
| 87493 | <1% | 703 | $21K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 6,190 | $21K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,197 | $21K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 75 | $20K |
| 82950 | <1% | 4,152 | $20K | |
| 84156 | <1% | 5,759 | $19K | |
| 86665 | <1% | 739 | $19K | |
| 36561 | <1% | 40 | $19K | |
| 86430 | <1% | 3,447 | $19K | |
| 97116 | <1% | 1,189 | $19K | |
| C1769 | Guide wire | <1% | 2,670 | $19K |
| 86696 | <1% | 1,087 | $19K | |
| 93270 | <1% | 799 | $18K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 99 | $18K |
| 83615 | <1% | 3,556 | $18K | |
| 29130 | <1% | 215 | $18K | |
| 97012 | <1% | 1,269 | $18K | |
| 86704 | <1% | 1,741 | $18K | |
| 74174 | <1% | 66 | $17K | |
| 82951 | <1% | 1,326 | $17K | |
| 83525 | <1% | 1,675 | $17K | |
| 86769 | <1% | 535 | $17K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,703 | $16K |
| 82627 | <1% | 886 | $16K | |
| 84425 | <1% | 872 | $16K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,016 | $16K |
| 84100 | <1% | 4,287 | $16K | |
| C8923 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography | <1% | 40 | $16K |
| 84207 | <1% | 606 | $15K | |
| 93925 | <1% | 101 | $15K | |
| R0070 | Transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, one patient seen | <1% | 646 | $14K |
| 87427 | <1% | 1,382 | $14K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 48 | $14K |
| 80306 | <1% | 1,965 | $14K | |
| 82977 | <1% | 2,045 | $14K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,961 | $14K |
| 74183 | <1% | 58 | $14K | |
| 29105 | <1% | 108 | $14K | |
| 88112 | <1% | 326 | $14K | |
| 84681 | <1% | 698 | $14K | |
| 86160 | <1% | 1,237 | $14K | |
| 87045 | <1% | 1,740 | $14K | |
| 99152 | <1% | 3,001 | $14K | |
| 82805 | <1% | 464 | $13K | |
| 82247 | <1% | 3,283 | $13K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,606 | $13K |
| 86361 | <1% | 554 | $13K | |
| 90675 | <1% | 52 | $13K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 866 | $13K |
| 72110 | <1% | 183 | $13K | |
| 86923 | <1% | 69 | $12K | |
| 88738 | <1% | 1,391 | $12K | |
| 82150 | <1% | 2,073 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,027 | $12K |
| 84165 | <1% | 1,251 | $12K | |
| 84480 | <1% | 963 | $12K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,407 | $12K |
| 87328 | <1% | 950 | $12K | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 160 | $11K |
| 86708 | <1% | 913 | $11K | |
| 76000 | <1% | 89 | $11K | |
| 83521 | <1% | 438 | $11K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 980 | $11K |
| 87075 | <1% | 912 | $11K | |
| 84144 | <1% | 580 | $10K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 816 | $10K |
| 77301 | <1% | 14 | $10K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 90 | $10K |
| 36416 | <1% | 1,837 | $10K | |
| 80164 | <1% | 842 | $9K | |
| 84460 | <1% | 2,133 | $9K | |
| 83655 | <1% | 574 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 291 | $9K |
| 72156 | <1% | 44 | $9K | |
| 82652 | <1% | 285 | $9K | |
| 84450 | <1% | 2,063 | $9K | |
| 82172 | <1% | 420 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,395 | $8K |
| Q0092 | Set-up portable x-ray equipment | <1% | 2,257 | $8K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 638 | $8K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 38 | $8K |
| 83883 | <1% | 758 | $8K | |
| 87329 | <1% | 827 | $8K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,979 | $8K |
| 86694 | <1% | 404 | $8K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,650 | $8K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,632 | $7K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 4,102 | $7K |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 488 | $7K |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 841 | $7K |
| 88173 | <1% | 186 | $7K | |
| 86304 | <1% | 481 | $7K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 304 | $7K |
| 80143 | <1% | 863 | $7K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,193 | $7K |
| 97166 | <1% | 86 | $7K | |
| 64615 | <1% | 21 | $7K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 267 | $7K |
| 82330 | <1% | 600 | $7K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,502 | $7K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 965 | $7K |
| 82105 | <1% | 459 | $7K | |
| 83986 | <1% | 1,508 | $6K | |
| 64400 | <1% | 30 | $6K | |
| 96401 | <1% | 61 | $6K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,358 | $6K |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,585 | $6K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 24 | $6K |
| 86695 | <1% | 428 | $6K | |
| 86709 | <1% | 496 | $6K | |
| 10005 | <1% | 20 | $6K | |
| L3808 | Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment | <1% | 30 | $5K |
| C1758 | Catheter, ureteral | <1% | 232 | $5K |
| 77280 | <1% | 110 | $5K | |
| 87807 | <1% | 877 | $5K | |
| 80179 | <1% | 679 | $5K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 59 | $5K |
| 73560 | <1% | 152 | $5K | |
| 84134 | <1% | 408 | $5K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 64 | $5K |
| 86787 | <1% | 397 | $5K | |
| 82010 | <1% | 1,280 | $5K | |
| 73200 | <1% | 57 | $5K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 592 | $5K |
| 72146 | <1% | 41 | $5K | |
| 16020 | <1% | 25 | $5K | |
| 71100 | <1% | 153 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,163 | $4K |
| 83695 | <1% | 376 | $4K | |
| 87625 | <1% | 203 | $4K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 20 | $4K |
| 86308 | <1% | 914 | $4K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 303 | $4K |
| 84155 | <1% | 1,303 | $4K | |
| 86677 | <1% | 269 | $4K | |
| 73660 | <1% | 117 | $4K | |
| 85046 | <1% | 1,025 | $4K | |
| 72197 | <1% | 20 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 597 | $4K |
| 85014 | <1% | 1,775 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 182 | $4K |
| 86225 | <1% | 330 | $4K | |
| 74178 | <1% | 14 | $4K | |
| 73521 | <1% | 54 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 50 | $4K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 453 | $4K |
| 81050 | <1% | 1,213 | $4K | |
| 73718 | <1% | 22 | $3K | |
| 72158 | <1% | 23 | $3K | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 90 | $3K |
| 84305 | <1% | 154 | $3K | |
| 82947 | <1% | 809 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,459 | $3K |
| 88185 | <1% | 12 | $3K | |
| 85018 | <1% | 1,854 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 962 | $3K |
| 76821 | <1% | 73 | $3K | |
| 86364 | <1% | 374 | $3K | |
| 80178 | <1% | 504 | $3K | |
| 89051 | <1% | 749 | $3K | |
| 86039 | <1% | 290 | $3K | |
| 87102 | <1% | 462 | $3K | |
| 83993 | <1% | 172 | $3K | |
| 82378 | <1% | 207 | $3K | |
| 77338 | <1% | 14 | $3K | |
| 72220 | <1% | 110 | $3K | |
| 86735 | <1% | 216 | $3K | |
| 83520 | <1% | 200 | $3K | |
| 72131 | <1% | 26 | $2K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 127 | $2K |
| 96402 | <1% | 40 | $2K | |
| 82274 | <1% | 122 | $2K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 533 | $2K |
| C1781 | Mesh (implantable) | <1% | 14 | $2K |
| 84520 | <1% | 753 | $2K | |
| 86258 | <1% | 187 | $2K | |
| 74021 | <1% | 67 | $2K | |
| 84270 | <1% | 109 | $2K | |
| 80305 | <1% | 416 | $2K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 13 | $2K |
| 86765 | <1% | 211 | $2K | |
| 86403 | <1% | 236 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 230 | $2K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 832 | $2K |
| 72202 | <1% | 28 | $2K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 45 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 163 | $2K |
| 76981 | <1% | 51 | $2K | |
| 82952 | <1% | 414 | $2K | |
| 86870 | <1% | 12 | $2K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 125 | $2K |
| 64445 | <1% | 54 | $2K | |
| R0075 | Transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, more than one patient seen | <1% | 176 | $2K |
| 82140 | <1% | 175 | $2K | |
| 84075 | <1% | 345 | $2K | |
| 87641 | <1% | 54 | $2K | |
| 15853 | <1% | 25 | $1K | |
| 86255 | <1% | 146 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 169 | $1K |
| 86800 | <1% | 95 | $1K | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 106 | $1K |
| 84132 | <1% | 409 | $1K | |
| 73060 | <1% | 83 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 629 | $1K |
| 97763 | <1% | 44 | $1K | |
| 86645 | <1% | 76 | $1K | |
| 81511 | <1% | 12 | $1K | |
| 94618 | <1% | 17 | $1K | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 22 | $1K |
| 84630 | <1% | 109 | $1K | |
| 76827 | <1% | 28 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,168 | $1K |
| 80202 | <1% | 89 | $1K | |
| 86644 | <1% | 76 | $994.14 | |
| 90686 | <1% | 100 | $943.11 | |
| 82390 | <1% | 89 | $936.23 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 107 | $935.95 |
| 83013 | <1% | 14 | $877.97 | |
| 86147 | <1% | 23 | $814.40 | |
| 82677 | <1% | 36 | $771.74 | |
| 82365 | <1% | 97 | $757.85 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 55 | $751.26 |
| 86705 | <1% | 67 | $746.48 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 577 | $671.41 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 322 | $654.91 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 78 | $648.69 |
| 85613 | <1% | 68 | $605.76 | |
| 97035 | <1% | 66 | $564.18 | |
| 82103 | <1% | 45 | $513.14 | |
| 86336 | <1% | 37 | $508.16 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 258 | $505.20 |
| 82180 | <1% | 54 | $460.45 | |
| 87015 | <1% | 86 | $456.79 | |
| 86812 | <1% | 25 | $452.61 | |
| 83921 | <1% | 26 | $427.62 | |
| 90674 | <1% | 30 | $415.80 | |
| 73600 | <1% | 13 | $397.90 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 339 | $379.92 |
| 85347 | <1% | 109 | $373.38 | |
| 86618 | <1% | 24 | $372.03 | |
| 83498 | <1% | 13 | $370.71 | |
| 77001 | <1% | 17 | $346.63 | |
| V2632 | Posterior chamber intraocular lens | <1% | 28 | $345.80 |
| 77399 | <1% | 12 | $344.74 | |
| 88184 | <1% | 22 | $342.00 | |
| 86341 | <1% | 14 | $336.48 | |
| 84446 | <1% | 31 | $317.47 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 58 | $313.43 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 35 | $313.25 |
| 82085 | <1% | 18 | $302.07 | |
| 73552 | <1% | 13 | $280.69 | |
| 90632 | <1% | 13 | $280.43 | |
| 88312 | <1% | 12 | $279.44 | |
| 70360 | <1% | 26 | $266.54 | |
| 84590 | <1% | 29 | $246.58 | |
| 84478 | <1% | 50 | $242.55 | |
| 36600 | <1% | 25 | $234.30 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 51 | $206.16 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 131 | $205.71 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 164 | $204.59 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 504 | $199.48 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 191 | $198.61 |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 30 | $195.99 |
| 86593 | <1% | 42 | $193.56 | |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 28 | $191.31 |
| 86381 | <1% | 13 | $183.24 | |
| 90714 | <1% | 24 | $181.52 | |
| 85045 | <1% | 52 | $176.46 | |
| 72170 | <1% | 13 | $158.90 | |
| J1240 | Injection, dimenhydrinate, up to 50 mg | <1% | 136 | $149.09 |
| 88720 | <1% | 29 | $145.58 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 133 | $142.44 |
| 82525 | <1% | 13 | $132.21 | |
| 81002 | <1% | 21 | $111.48 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 475 | $107.48 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 845 | $91.80 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 236 | $74.65 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 312 | $74.11 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 259 | $72.69 |
| 84300 | <1% | 19 | $64.57 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 69 | $62.50 |
| 84157 | <1% | 27 | $57.27 | |
| A9270 | Non-covered item or service | <1% | 1,645 | $46.25 |
| 85049 | <1% | 15 | $45.92 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 48 | $23.32 |
| 82945 | <1% | 12 | $22.81 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 45 | $19.79 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 29 | $18.52 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 16 | $17.95 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 17 | $14.97 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 483 | $14.93 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 67 | $11.52 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 50 | $2.64 |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 30 | $0.08 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 55 | $0.02 |
| J3590 | Unclassified biologics | 0% | 131 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRITCHEY-BALDWIN, LORI (CFO)
| Provider | Location | Paid |
|---|---|---|
| ST Elizabeth Medical Center, INC | Florence, KY | $65.44M |
| ST Elizabeth Medical Center, INC | Fort Thomas, KY | $45.99M |
| ST Elizabeth Medical Center, INC | Williamstown, KY | $35.42M |
| ST Elizabeth Medical Center, INC | Lawrenceburg, IN | $4.66M |
| ST Elizabeth Medical Center, INC | Erlanger, KY | $3.75M |
| ST Elizabeth Medical Center, INC | Edgewood, KY | $2.95M |
| ST. Elizabeth Medical Center, INC. | Edgewood, KY | $438.18 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.